ERBB2 and breast carcinoma: We found that in a cohort of 398 patients with ErbB2/Her2-positive breast carcinoma, increased BLNK mRNA expression is significantly associated with increased disease-free survival: p-value = 0.0018, hazard ratio = 0.6 (95% CI 0.43–0.83) (Fig. 9).